Chemotherapy
Microbiology
Mycophenolic Acid Inhibits Replication of Japanese Encephalitis VirusSebastian L. · Madhusudana S.N. · Ravi V. · Desai A.Department of Neurovirology, National Institute of Mental Health and Neuro Sciences, Bangalore, India
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: December 03, 2009
Accepted: July 19, 2010
Published online: February 01, 2011
Issue release date: March 2011
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 0
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Abstract
Background: Japanese encephalitis is a major public health problem in several parts of Asia, particularly India, Nepal, Sri Lanka and Myanmar (Burma). Despite its public health implications, there are no effective antiviral drugs available. Methods: The present study evaluated the effect of mycophenolic acid on Japanese encephalitis virus (JEV) using an in vitro cytopathic effect inhibition assay, plaque reduction assay and virus yield reduction assay, and its therapeutic potential was also assessed in vivo in a mouse model. Results: Analysis of the results obtained in the in vitro and in vivo experiments suggests that mycophenolic acid has significant antiviral activity against JEV, with an IC50 of 3.1 µg/ml, a therapeutic index of 16 and a 75% protection against lethal challenge of JEV. Conclusion: The study concludes that this compound significantly inhibited the replication of JEV in vitro and protected mice in vivo.
© 2011 S. Karger AG, Basel
Related Articles:
References
- Chen CJ, Raung SL, Kuo MD, Wang YM: Suppression of Japanese encephalitis virus infection by non-steroidal anti-inflammatory drugs. J Gen Virol 2002;83:1897–1905.
- Morrey JD, Smee DF, Sidwell RW, Tseng C: Identification of active antiviral compounds against a New York isolate of West Nile virus. Antivir Res 2002;55:107–116.
- Markland W, McQuaid TJ, Jain J, Kwong AD: Broad spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral activity with alpha interferon. Antimicrob Agents Chemother 2000;44:859–866.
-
De Clercq E: Virus replication: target functions and events for virus-specific inhibitors; in Antiviral Agents and Human Viral Diseases, ed 4. Philadelphia, Lippincott-Raven, 1997, pp 1–42.
- Neyts J, Meerbach A, McKenna P, De Clercq E: Use of the yellow fever virus vaccine strain-17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res 1996;30:125–132.
- Diamond MS, Zachariah M, Harris E: Mycophenolic acid inhibits Dengue virus infection by preventing replication of viral RNA. Virology 2002;304:211–221.
- Crance JM, Scarmozzino N, Jouan A, Garin D: Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flavivirus. Antivir Res 2003;58:73–79.
- Sebastian L, Desai A, Madhusudana SN, Yogeeswari Y, Sriram D, Ravi V: N-methylisatin-beta-t thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese encephalitis virus infection in vitro and in vivo. Virol J 2008;5:64.
- Sebastian L, Desai A, Madhusudana SN, Yogeeswari Y, Sriram D, Ravi V: Pentoxifylline inhibits replication of Japanese encephalitis virus: a comparative study with ribavirin. Int J Antimicrob Agents 2009;33:168–173.
- Kumar R, Mathur A, Kumar A, Sethi GD, Sharma S, Chaturvedi UC: Virological investigations of acute encephalopathy in India. Arch Dis Child 1990;65:1227–1230.
-
Monath TP: Flaviviruses; in Field BN, Knipe DM (eds): Virology. New York, Raven, 1990, pp 763–814.
- Leyssen P, Balzarini J, De Clercq E, Neyts J: The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 2005;79:1943–1947.
- Takhampunya R, Ubol S, Houng H, Cameron CE, Padmanabhan R: Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J Gen Virology 2006;87:1947–1952.
- Sintchak MD, Fleming MA, Futer O, et al: Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996;85:921–930.
- Durez P, Appelboom T, Pira C, Stordeur P, Vray B, Goldman M: Anti-inflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-alpha and upregulation of IL-10 release. Int J Immunopharmacol 1999;21:581–587.
- Baer PC, Wegner B, Geiger H: Effects of mycophenolic acid on IL-6 expression of human renal proximal and distal tubular cells in vitro. Nephrol Dial Transplant 2004;19:47–52.
- Ravi V, Parida S, Desai A, Chandramukhi A, Gourie-Devi M, Grau GE: Correlation of tumor necrosis factor levels in the serum and cerebrospinal fluid with clinical outcome in Japanese encephalitis patients, J Med Virology 1997;51:132–136.
- Winter PM, Dung NM, Loan HT, Kneen R, Wills B, Thu LT, House D, White N, Jeremy J, Farra JJ, Hart CA, Solomon T: Pro-inflammatory cytokines and chemokines in humans with Japanese encephalitis. J Infect Diseases 2004;190:1618–1626.
- Subramanian GM, Moore PA, Gowen BB, Olsen Al, Barnard DL, Paragas J, Hogan RJ, Sidwell RW: Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus. Chemotherapy 2008;54:176–180.
- Harinasatu C, Nimmanitya S, Titsyakorn U: The effect of interferon on two cases of Japanese encephalitis in Thailand. Southeast Asian J Trop Med Public Health 1985;16:332–336.
- Schäfer A, Scheurlen M, Weissbrich B, Schöttker K, Kraus MR: Sustained virological response in the antiviral therapy of chronic hepatitis virus C: is there a predictive value of interferon-induced depression? Chemotherapy 2007;53:292–299.
- Vanrenterghem Y: The use of mycophenolate mofetil (Cellcept) in renal transplantation. Nephron 1997;76:392–399.
Article / Publication Details
Received: December 03, 2009
Accepted: July 19, 2010
Published online: February 01, 2011
Issue release date: March 2011
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 0
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
